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The release of hormones from thyroxine-binding globulin
(TBG) and corticosteroid-binding globulin (CBG) is regulated
by movement of the reactive center loop in and out of the
-sheet A of themolecule. To investigate how these changes are
transmitted to the hormone-binding site, we developed a sensi-
tive assay using a synthesized thyroxine fluorophore and solved
the crystal structures of reactive loop cleavedTBG togetherwith
its complexes with thyroxine, the thyroxine fluorophores, furo-
semide, and mefenamic acid. Cleavage of the reactive loop
results in its complete insertion into the -sheet A and a sub-
stantial but incomplete decrease in binding affinity in bothTBG
and CBG. We show here that the direct interaction between
residue Thr342 of the reactive loop and Tyr241 of the hormone
binding site contributes to thyroxinebinding and release follow-
ing reactive loop insertion.However, amuch larger effect occurs
allosterically due to stretching of the connecting loop to the top
of the D helix (hD), as confirmed in TBG with shortening of the
loop by three residues, making it insensitive to the S-to-R tran-
sition. The transmission of the changes in the hD loop to the
binding pocket is seen to involve coherent movements in the
s2/3B loop linked to the hD loop by Lys243, which is, in turn,
linked to the s4/5B loop, flanking the thyroxine-binding site, by
Arg378. Overall, the coordinated movements of the reactive
loop, hD, and the hormone binding site allow the allosteric reg-
ulation of hormone release, as with the modulation demon-
strated here in response to changes in temperature.
Thyroxine (tetraiodothyronine; T4)2 controls the rate of
metabolism and the corticosteroid hormones regulate the
inflammatory response in humans. They are carried predomi-
nantly in the blood and released in the tissues by thyroxine-
binding globulin (TBG) and corticosteroid-binding globulin
(CBG), respectively. Both proteins are noninhibitory members
of the serpin family of serine protease inhibitors (1, 2), and both
have adapted the characteristic conformational mechanism of
the serpins to allow the release of the carried hormones (3–5).
Recent crystallographic studies (see Fig. 1) have shown how
the hormones bind similarly to an equivalent pocket on the
surface of each of the two binding globulins (6, 7). The crystal
structure of a TBG-thyroxine complex indicated how this
reversible binding and release could result from a flip-flop
change in conformation due to the partial movement of the
intact reactive center peptide loop of TBG into and out of the A
-sheet of themolecule (6). An indication as to how this limited
movement of the loop could influence the conformation of the
hormone binding pocketwas provided by the subsequent struc-
tures of the native rat CBG-corticosteroid complex (7) and
reactive loop-cleaved humanCBG (8). In the native CBG struc-
ture, the reactive loop is fully exposed, and the peptide loop
connecting strand 2 of the -sheet A to the top of helix D (hD)
is in a helical conformation (see Fig. 1A). However, when the
reactive center loop is cleaved, CBG undergoes the typical ser-
pin S-to-R transition (8–11), with the insertion of the cleaved
reactive loop into the -sheet A as a middle strand and the
unwinding of the connecting loop on top of hD due to the
-sheet A expansion (see Fig. 1C). It was proposed (6–8) that
hormone binding and release is controlled through an allosteric
mechanism similar to that of the heparin activation of anti-
thrombin, a serpin controlling blood coagulation (12, 13). As
illustrated in Fig. 1D (8), the binding globulins can undergo
equilibrated shifts between high and low affinity conforma-
tions, with the lowest affinity form resulting from the irrevers-
ible S-to-R transition, as occurs with gross proteolytic exposure
at sites of inflammation (9–11, 14, 15).
The aims here are to investigate the preceding reversible
stages (I–III in Fig. 1D), involving the initial insertion of the
reactive loop together with the concerted changes at the top of
helix D that result from the expansion of the -sheet A and to
show how these changes are transmitted to the hormone-bind-
ing site. To assess the contributions of individual elements of
this mechanism to changes in TBG binding affinity, we have
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developed a sensitive assay using synthesized thyroxine fluoro-
phores. This assay has enabled us to demonstrate the regulatory
potential of the allosteric mechanism in TBG as well as CBG, as
shown here with the temperature-dependent modulation of
hormone release.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—Recombinant wild-
type human TBG (UniProKb accession no. P05543) was pre-
pared as described previously (6). The reactive center loop
cleavedTBGwas prepared by incubating native TBGwithHNE
at 200:1 ratio at room temperature for 2 h and purified by a
Hitrap-HQ column (Amersham Biosciences Bioscience). A
TBG-D3mutant was engineered with its connecting loop from
helix D to strand 2 of the-sheet A (hDs2A) shortened by three
residues by replacement of the four residues 103–106 with a
single Ala. Two other mutants were similarly prepared, replac-
ing Lys243, which closely packs with the hDs2A connecting
loop, by either Gly (TBG-K243G) or Ala (TBG-K243A). Both
the native and cleaved forms of the mutants were assessed for
their binding affinities.
To more readily enable the preparation of the relaxed con-
former, a segment of the reactive loop of TBG (P10-P1) was
substitutedwith that of antitrypsin Pittsburgh (GAMFLEAIPR-
SIP) (16), which can be specifically cleaved at Arg by thrombin.
This variant, termedTBG-Atl, was used for subsequent crystal-
lization and binding affinity studies with thyroxine and its ana-
logues. A further mutant based on TBG-Atl was also prepared,
where Arg378, which interacts with both the thyroxine and the
s2/3B loop, was replaced by Gly. All other binding affinities (as
in Table 2) and modifications utilized wild-type TBG. Recom-
binant human CBG was prepared using the SUMO expression
system with an N terminus of 11SNHHRGLA…, starting from
residue 11 of the mature protein with protocols for expression,
purification, and characterization as described previously (8).
Preparation of L-thyroxine-5- and 6-carboxyfluorescein—
Based on previous conjugate formation (17) with the scheme
shown below (see Fig. 3A), a1/1 mixture of 5-and 6-carboxy-
fluorescein (0.5 g and 1.33 mmol) was dissolved at ambient
temperature in dry N,N-dimethylformamide as the reaction
solvent (13.3 ml) in a 10-ml round bottom flask with magnetic
stirring. N-hydroxysuccinamide (230 mg, 1.99 mmol) and
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochlo-
ride salt (382 mg, 1.99 mmol) were added successively. After
20 h, the resulting 0.1 M solution of crude activated 5(6)-car-
boxyfluorescein was used directly for the next step. Coupling of
L-thyroxine with activated 5(6)-carboxyfluorescein was carried
out in a 10 ml round bottom flask. L-Thyroxine (50 mg, 0.064
mmol) was suspended in dry N,N-dimethylformamide (0.64
ml) and the 0.1 M solution of crude activated 5(6)-carboxyfluo-
rescein (0.7 ml, 0.07 mmol) was added. N,N-diisopropylethyl-
amine (22l, 0.12mmol) was then added drop-wise to give to a
homogeneous orange solution. After 4 h, the solution was
cooled in an ice bath and acidifiedwith trifluoroacetic acid (29.6
l, 0.348 mmol). The solvents were removed in vacuo. The
crude mixture was purified by reverse phase HPLC with a C18
column and an isocratic 60/40 mixture of MeCN/H2O (0.1%
formic acid) as the mobile phase to afford separately the
two fluorophores, L-thyroxine-6-carboxyfluorescein (termed
T4–6-CF, 23.4 mg, 0.0206 mmol, bright yellow) and L-thyrox-
ine-5-carboxyfluorescein (termed T4–5-CF, 22.3 mg, 0.0196
mmol, pale yellow). The identities of these two conjugates were
confirmed byNMRstudies. (L-thyroxine-6-carboxyfluorescein:
H (500 MHz, d6-DMSO): 10.15 (br, 2H, OH), 8.83 (br, 1H,
NH), 8.10 (d, 1H, J 8.0), 8.03 (d, 1H, J 8.0), 7.72 (br, 3H), 6.98 (s,
2H), 6.68 (d, 1H, J 2.2), 6.66 (d, 1H, J 2.2), 6.562 (d, 1H, J 8.7),
6.557 (d, 1H, J 8.7), 6.54 (dd, 1H, J 8.7 and 2.2), 6.52 (dd, 1H, J 8.7
and 2.2), 4.46–4.54 (m, 1H), 3.12 (dd, 1H, J 13.2 and 4.1), 2.85
(m, 1H). ESI Calc. 1135.7422 [MH], found 1135.7454;
L-thyroxine-5-carboxyfluorescein, H (500 MHz, d6-DMSO):
10.16 (br, 2H,OH), 9.04 (d, 1H, J 9.0, NH), 8.44 (s, 1H), 8.17 (dd,
1H, J 8.0 and 1.4), 7.88 (s, 2H), 7.35 (d, 1H, J 8.0), 7.00 (s, 2H),
6.67 (d, 2H, J 2.2), 6.560 (d, 1H, J 8.6), 6.545 (d, 1H, J 8.6), 6.51
(dd, 1H, J 8.6 and 2.2), 6.505 (dd, 1H, J 8.6 and 2.2), 4.74–4.67
(m, 1H), 3.24 (dd, 1H, J 13.5 and 4.2), 3.00 (dd, 1H, J 13.5 and
10.9). ESI Calc. 1135.7422 [MH], found 1135.7433).
Crystallization and Data Collection—All the crystallization
studies were based on the TBG-Atl variant. The reactive loop
cleavedTBG(cTBG)was concentrated in 10mMTris-HCl, 50mM
NaCl, 1 mM EDTA, pH 7.4, and crystallized in sitting drops con-
taining 1l of protein (15mg/ml) and 1l of precipitant solution
(20% PEG 3350 with 0.2 M CaCl2 or Na2SO4, pH 5.4) at 23 °C for
1 week. To soak in thyroxine or other analogues, cTBG crystals
FIGURE 1. The allosteric mechanism of hormone binding and release.
Native CBG (A) has a fully exposed reactive center loop (RCL) with a connect-
ing loop on top of helix D (green, arrow) in a helical conformation. This loop is
unwound following partial insertion of the reactive loop as seen in the native
TBG structure (B) or full insertion into the central -sheet A in the reactive
loop-cleaved CBG structure (C). D, the changes in flexibility of hD resulting
from the dynamic flip-flopmovement of the reactive loop are transmitted to
the hormone binding pocket. I, native CBG, with a reactive loop four residues
shorter than that of TBG, crystallizes in the fully exposed loop conformation
with a high binding affinity. II, native TBG crystallizes in the partly inserted
loop conformation with an intermediate affinity for thyroxine but equili-
brates toward frame Iwith higher affinitywhen the reactive loop is shortened
or toward III with lower affinity when the loop is extended (29). Both native
TBGandCBGcanequilibrate among these loop-sheet configurations, and the
changes in the binding affinity result from the changes of the relative popu-
lations of each conformer of different loop-sheet configurations. IV, protease
cleavage of the reactive loop results in its incorporation into the central
-sheet A to form, typically irreversibly, a stable relaxed conformation with
the lowest binding affinity.
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were transferred into the corresponding precipitant solution con-
taining corresponding ligands and soaked for12 h. The crystals
were cryoprotected with 15% glycerol and flash-cooled in liquid
nitrogen.Thedata set for cTBG(1.5Å)was collected atDaresbury
Synchroton Radiation Source Station 14.1 and the data set for its
complexwith thyroxine (2Å)wascollected in-house.Thedata sets
for cTBG soaked with T4–6-F, T4–5-F, mefenamic acid, and
furosemide were collected at Diamond Light Source station I02.
Data were processed by Mosflm (18) and scaled with Scala (19).
The initial structure of cTBG was solved by molecular replace-
ment with Phaser (20) using coordinates of cleaved antitrypsin
(ProteinData Bank code 1QMB) (21) as a searchmodel.One copy
of cTBGwas found for the cTBG and cTBG-thyroxine structures.
Themodels were built in Coot (22) and refinedwith TLS (transla-
tion, liberation, screw motion) parameters in Refmac5 (23). Sub-
sequent structuresof cTBGwithdifferent ligandswere solvedsim-
ilarly using cTBG as the searchmodel. The T4 fluoresceinmodels
were built in Sketcher (CCP4 suite) and the coordinates of other
thyroxine analogues were from the CCP4 library. T4–5-CF and
T4–6-CF were refined with partial occupancy in the structure.
Although both T4 fluorescein analogues can be readily modeled
and refined in the structures, the electrondensities for the fluores-
ceinmoiety are weak, indicating greater flexibility in this region of
the ligand.All structureswere refinedwithgoodgeometry, and the
final refinement statistics are listed inTable 1. The atomic coordi-
nates and structure factors have been deposited in the Protein
Data Bank (Table 1). The secondary structure was assigned by the
program DSSP (24). The figures were created using the open
source program PyMOL using the following coordinates: native
humanTBG-thyroxine complex (ProteinData Bank code 2CEO),
native rat CBG-cortisol complex (Protein Data Bank code 2V6D),
and reactive loop cleaved human CBG (Protein Data Bank codes
2VDX and 2VDY).
Binding Affinities—Fluorescence titration experiments were
performed using a LS50B luminescence spectrometer (Perkin-
Elmer Life Sciences). Formeasuring the binding affinities of the
CBG conformer to cortisol, aliquots of cortisol were titrated
into 0.8 ml, 100 nM of CBG in phosphate-buffered saline con-
taining 0.1% (w/v) PEG 8000 at the desired temperature, with
quenching in intrinsic protein fluorescence of CBG monitored
at 340 nm with an excitation at 290 nm. The dissociation con-
stant (Kd) of binding was obtained by fitting the changes in
fluorescence signalwith the concentrations of cortisol using the
quadratic equilibrium binding equation.
F
FO

Fmax
FO

Kd Flu L Kd [Flu L)2 4 [Flu] L
2 [Flu]
(Eq. 1)
In this equation, F represents the change in fluorescence fol-
lowing each addition of ligand (cortisol) from the initial fluo-
rescence FO, andFmax represents the maximal change of fluo-
rescence intensity of CBG. Here, [Flu] [CBG].
Thyroxine binding studies were performed at defined tem-
peratures in phosphate buffer containing 0.1% (w/v) PEG 8000
and 0.2 mg/ml antitrypsin (which does not bind thyroxine
derivatives). TBG stock solution prepared in the same buffer
was gradually added into theT4 fluorophore derivative solution
(1–2 nM) with fluorescence intensity of T4 fluorophore moni-
tored at 530 nm (excitation wavelength ex  495 nm) with a
cutoff at 515 nm. The slit widths on the excitation and emission
sidewere 2.5 and 15nm, respectively. The dissociation constant
of binding (Kd) was obtained by fitting the changes in fluores-
cence signal of the individual T4 derivatives with the concen-
trations of TBG using the binding equation shown above. Due
to the detection limitation of the equipment, the fluorescence
signal cannot bemeasured confidently when the concentration
of T4 fluoresceins under test is 	0.5 nM, which means that Kd
values 	0.05 nM are likely to be inaccurate (25). Therefore,
T4–6-CF, which has a lower binding affinity with TBG, was
chosen for subsequent affinitymeasurements of TBG conform-
ers. The binding affinity of 8-anilino-1-naphthalenesulfonate
with TBG was measured similarly with the fluorescence signal
of 8-anilino-1-naphthalenesulfonate monitored at 475 nm
(ex 375 nm) following TBG titration.
A competitive assay was used tomeasure the binding affinity of
thyroxine and its analogues, such as mefenamic acid and furo-
semide. Briefly, aliquots of the analogues were titrated into amix-
ture of TBG and T4 fluorophore in phosphate buffer containing
0.1% (w/v) PEG 8000, and the changes in fluorescence intensity at
530 nm (ex  495 nm) with a cutoff at 515 nm was monitored.
The dissociation constant of the analog (Ki) was obtained by non-
linear curve fit using Equation 2. (Details of how this equation is
derived are shown in the supplemental material.)
Lt   Rt  PR Kd PRPt PR
 Ki Pt PR
Kd PR  1 (Eq. 2)
All parameters except for [PR] are constant. R represents the
receptor (TBG) of the ligands, P represents probes (T4–6-CF),
Kd represents the dissociation constant of P and R binding, Ki
represents the dissociation constant of competitive ligand, and
[PR]o represents initial concentration of the complex of recep-
tor and probe. [PR] is derived from the measured fluorescence
changes following addition of competitive ligands,
PR
F
Fo
PRo (Eq. 3)
where Fo represents the initial change in fluorescence when the
probe (T4–6-CF) complexes with the receptor (TBG), and F
represents the changes of fluorescence following addition of the
competitor ligand. All of the Kd measurements are repeated at
least three times, and themeans S.D. are shown in the tables.
RESULTS
Structures of Reactive Loop-cleaved TBG—The crystal struc-
tures of cleaved human TBG and its complex with T4 were
solved at 1.5 and 2.0 Å resolution, respectively, with good
geometry (Table 1). As expected, TBG undergoes the typical
overall S-to-R (stressed-to-relaxed) conformational changes
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observed with inhibitory serpins, with the full incorporation of
the exposed reactive loop into the central -sheet A (Fig. 2). In
keeping with observations that the S-to-R transition results in a
decrease rather than a complete loss of binding affinity, crystals
of cTBG readily formed complexes upon soaking with thyrox-
ine (Fig. 2) with clear electron density for the bound hormone.
The binding site of cTBG is substantially unchanged with only
small alterations in side chain interactions between thyroxine
and cTBG (supplemental Fig. S1A). The thyroxine-binding site
lies betweenhelicesH andA,with the thyroxine held in place by
interactions with principally the side chains of residues in helix
H and in the peptide loop of strands 4 and 5 of the underlying
-sheet B. The key residues in this s4/5B loop further form a
network of interactions with the preceding loop connecting
strands 2 and 3 of the -sheet B (s2/3B). These key stabilizing
interactions of thyroxine are retained in the cleaved TBG
including salt-bridges formed by Arg378 and the stacking of
Arg381 with the lower aromatic ring of thyroxine (Fig. 2C).
Arg378 is further stabilized by a watermolecule, which interacts
with the main chain carboxyl oxygen atoms of Tyr241 and
Ala245. Furthermore, residue Tyr20 of helix A, which is resolved
FIGURE 2. The thyroxine-binding site. A, the binding site of the native
TBG-T4 complex. B, TBG undergoes the typical S-to-R transition with the
exposed reactive loop (yellow) on cleavage being fully inserted into the cen-
tral A-sheet (red). The cleaved form retains the ability to bind thyroxine (in
sphereswith carbon atoms in gray, oxygen atoms in red, iodine atoms in pur-
ple, and nitrogen atoms in blue) in the same binding site as seen in the native
TBG-thyroxine complex (supplemental Fig. S1). C, binding is mainly through
hydrophobic interactions stabilized by a network of hydrogen bonds sur-
rounding the binding site. The connecting loop on top of hD (in green) inter-
acts with the s2/3B loop (purple) though Lys243. Arg378 of s4/5B loop is stabi-
lized by forming salt bridges with Asp240 of s2/3B and directly with thyroxine
(carbon atoms shown in dark gray sticks). Arg378 is further linked to the main
chain of s2/3B loop by forming a hydrogen bond with a water molecule (red
ball). Salt bridges and hydrogen bonds are shown as black dashed lines.
T
A
B
LE
1
C
ry
st
al
lo
g
ra
p
h
ic
d
at
a
co
lle
ct
io
n
an
d
re
fi
n
em
en
t
st
at
is
ti
cs
cT
BG
cT
BG
-th
yr
ox
in
e
cT
BG
-T
4–
5-
CF
cT
BG
-T
4–
6-
CF
cT
BG
-m
ef
en
am
ic
ac
id
cT
BG
-fu
ro
se
m
id
e
Da
ta
co
lle
ct
io
n
Sp
ac
eg
ro
up
P2
12
12
P2
12
12
P2
12
12
P2
12
12
P2
12
12
P2
12
12
Un
it-
ce
ll
pa
ra
m
et
er
s(
a,
b,
c(
Å)
; 	
,
,

)
17
3.1
4,
42
.59
,5
5.9
9;
90
,
90
,9
0°
17
3.5
9,
42
.16
,5
5.9
8;
90
,9
0,
90
°
17
4.0
3,
42
.55
,5
6.2
2;
90
,
90
,9
0°
17
2.6
9,
42
.14
,5
6.1
;9
0,
90
,
90
°
17
2.8
4,
41
.63
,5
6.1
9;
90
,9
0,
90
°
17
2.8
8,
42
.15
,5
6.1
9;
90
,
90
,9
0°
So
lve
nt
co
nt
en
t(
%)
48
48
48
48
48
48
M
ol
ec
ul
es
pe
ra
sy
m
m
et
ric
un
it
1
1
1
1
1
1
Re
so
lu
tio
n
ra
ng
e
29
.5–
1.5
(1
.58
–1
.5)
23
.5–
2.0
3(
2.1
4–
2.0
3)
34
.41
–1
.43
(1
.51
–1
.43
)
29
.41
–1
.28
5(
1.3
5–
1.2
8)
21
.97
–2
.09
(2
.21
–2
.09
)
34
.58
–1
.70
(1
.79
–1
.70
)
Un
iq
ue
re
fle
ct
io
n
66
,48
1(
87
29
)
26
,88
1(
34
07
)
72
,97
3(
53
58
)
95
,94
1(
69
06
)
24
,69
2(
31
37
)
40
,38
2(
19
56
)
Av
er
ag
er
ed
un
da
nc
y
6.8
(4
.5)
3.3
(3
.0)
3.5
(3
.4)
3.6
(3
.6)
5.2
(3
.3)
3.7
(3
.6)
Co
m
pl
et
en
es
s(
%)
98
.6
(9
0.4
)
97
.7
(8
6.5
)
99
.2
(9
9.8
)
96
.3
(9
5.7
)
98
.2
(8
8.5
)
92
.6
(7
1.1
)
Av
er
ag
eI
/ 
28
.9
(7
.5)
16
.4
(4
.9)
8.5
(2
.0)
9.2
(2
.5)
14
.5
(3
.3)
4.3
(1
.7)
R m
er
ge
0.0
41
(0
.22
2)
0.0
56
(0
.16
8)
0.0
7(
0.4
94
)
0.0
7(
0.6
37
)
0.0
91
(0
.32
2)
0.1
94
(0
.54
7)
R m
ea
s
0.0
48
(0
.29
1)
0.0
77
(0
.23
2)
0.0
81
(0
.58
5)
0.0
81
(0
.73
4)
0.1
09
(0
.39
8)
0.2
22
(0
.62
8)
Re
fin
em
en
ts
ta
tis
tic
s
N
o.
of
re
sid
ue
s
37
3
36
8
37
3
37
1
37
2
37
5
N
o.
of
re
fin
ed
at
om
s
34
82
32
84
33
60
33
88
30
84
33
23
N
o.
of
so
lve
nt
m
ol
ec
ul
es
42
8
29
5
29
8
32
0
13
1
28
2
R
va
lu
e
0.1
88
0.1
98
0.2
00
0.2
09
0.2
13
0.2
06
R f
re
e
va
lu
e
0.2
14
0.2
43
0.2
18
0.2
35
0.2
60
0.2
32
r.m
.s.
bo
nd
len
gt
h
(Å
)a
0.0
10
0.0
09
0.0
08
0.0
06
0.0
11
0.0
08
r.m
.s.
bo
nd
an
gle
s
1.3
20
°
1.1
85
°
1.2
75
°
1.1
87
°
1.2
58
°
1.1
04
°
Ra
m
ac
ha
nd
ra
n
pl
ot
(fa
vo
re
d/
ou
tli
er
s,
%)
98
.64
/0
98
.64
/0
99
.19
/0
98
.91
/0
98
.1/
0
98
.65
/0
M
ea
n
B-
fa
ct
or
18
.8
21
.1
21
.9
17
.6
32
.8
20
.0
M
ol
Pr
ob
ity
sc
or
eb
96
th
pe
rc
en
til
e(
n

48
36
,
1.5
0
0.2
5Å
)
99
th
pe
rc
en
til
e(
n

12
,11
2,
2.0
4
0.2
5Å
)
95
th
pe
rc
en
til
e(
n

34
04
,
1.4
3
0.2
5Å
)
94
th
pe
rc
en
til
e(
n

21
01
,
1.2
9
0.2
5Å
)
98
th
pe
rc
en
til
e(
n

11
,61
8,
2.0
9
0.2
5Å
)
98
th
pe
rc
en
til
e(
n

92
48
,
1.7
0
0.2
5Å
)
PD
B
co
de
2R
IV
2R
IW
2X
N
7
2X
N
6
2X
N
3
2X
N
5
a
r.m
.s.
,r
oo
tm
ea
n
sq
ua
re
;P
DB
,P
ro
te
in
Da
ta
Ba
nk
.
b
10
0t
h
pe
rc
en
til
ei
st
he
be
st
am
on
gs
tru
ct
ur
es
of
co
m
pa
ra
bl
er
es
ol
ut
io
n;
0t
h
pe
rc
en
til
ei
st
he
wo
rs
t.
Allosteric Modulation of Hormone Release
16166 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 18•MAY 6, 2011
poorly in the native TBG-thyroxine complex structure, is seen
in cTBGand its complexwith thyroxine to interact withArg381.
This mirrors the cation- stacking interaction of Arg10 with
Trp371 in structures of the CBG-cortisol complex (6–8). Of
special note in cTBG is the realignment of the side chains from
Tyr20 and Arg381 to allow the binding of thyroxine into the
binding pocket with consequent shifting of the N terminus of
hA (supplemental Fig. S1).
T4 Fluorophores and Binding Affinities—TBG has a tight
binding affinity for T4 (Kd  0.1 nM) (26) and the binding and
release of thyroxine from TBG cannot be monitored readily by
direct fluorimetry. Therefore, to fluorimetrically correlate the
changes in binding affinity in TBG with its changes in confor-
mation, two fluorescent T4 conjugates were synthesized, L-thy-
roxine-5-carboxyfluoroscein and L-thyroxine-6-carboxyfluo-
roscein (designatedT4–5-CF andT4–6-CF), with the carboxyl
group of fluorescein coupled to the amine group of thyroxine
(Fig. 3A). The crystal structures of each of theT4 fluoresceins in
complex with cleaved TBG were solved at a resolution of 1.5
and 1.3 Å resolution (Table 1 and supplemental Fig. S1). The
structures confirm that binding takes place through their T4
moiety with the same orientation and contacts within the thy-
roxine-binding pocket as those of unmodified thyroxine (6). As
shown in Fig. 3B, the two thyroxine derivatives have a similar
basal fluorescent emission when excited at 490 nm. However,
they have different fluorescent characteristics on binding of
TBG. The binding of TBG with T4–6-CF results in a 200%
enhancement of the fluorescence, whereas the binding of TBG
with T4–5-CF results in a75% decrease in fluorescent inten-
sity. The binding affinities of the T4-fluorophores with TBG
were determined by fluorescent titration at 22 °C, with the
gradual addition of TBG to solutions of the T4 derivatives. TBG
binds T4–6-CFwith a dissociation constant of 2.2 nM (Fig. 3C),
whereas TBG binds T4–5-CF very tightly with a Kd estimated
less than 0.1 nM.Hence, T4–6-CF, with a lower binding affinity
allowing convenient fluorescence measurement, was used to
assess and correlate changes in affinity with changes in confor-
mation. Notably, the reactive loop cleaved wild-type TBG was
shown to bind T4–6-CF with a Kd of 12.2 nM, indicating a
5.5-fold increase comparedwith the native form (Fig. 3C). Con-
firmation of the relevance and validity of this approach came
from the measurement of the binding affinity of TBG toward
T4 by a competitive assay with the T4 fluorophore. Although
the measurement error is relatively large for the Kd of native
TBG (0.04 nM) at 22 °C due to the tightness of the binding
and the limitation in detecting small fluorescence signal
changes, a similar 5-fold change in T4 binding affinity with
cleaved TBG (Kd 0.2 nM) was observed. Further confirmation
of the direct relevance of the T4–6-CF fluorophore came from
its use to competitively determine the larger, and hence more
FIGURE 3. Thyroxine fluorophores. A, fluorophores were conjugated to thyroxine through chemical synthesis (as described under “Experimental Proce-
dures”). B, the conjugates have similar basal fluorescence spectra (dashed lines) when excited at 490 nm,which differ however on binding to TBG. TBG binding
of T4–6-CF (thick line) results in a near 200% enhancement in fluorescence at 525 nm, whereas binding of T4–5-CF (thin line) results in a 75% decrease in
fluorescence signal. C, the binding affinities of native TBG (circles) and reactive loop-cleaved TBG (triangles) were obtained by titrating TBG into solutions of
T4–6-CF with fluorescence changes plotted against protein concentrations. The curves were fitted with the quadratic equilibrium binding equation I.
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accurately measured, Kd of T4 with TBG at 37 °C. The Kd value
of 0.075 nM obtained here is in good agreement with literature
values (27).
Role of Helix D and Its interactions with Hormone-binding
Site—Our previous structural studies of cleaved CBG showed
that the expansion of -sheet A resulted in a lengthening of the
peptide loop connecting it to the top of helix D (hDs2A), with
the extension being provided by a partial unwinding of the
helix. The structures indicated that the transmission of changes
on the unwinding of helix D to the hormone-binding site in
cleaved CBG are due to the extended connecting loop bending
toward and interacting with the edge of the binding site. In the
structure of native TBG, however, the reactive loop is already
partially inserted and, consequently, no significant change
takes in the connecting loop of TBG upon cleavage (supple-
mental Fig. S1). To test whether the induced extension of the
connecting loop from the top of helix D alsomediates hormone
release in TBG, we engineered a TBG mutant with three resi-
dues deleted from the connecting loop. This mutant (TBG-D3)
has a considerably increased Kd of 25 nM as compared with the
Kd of wild-type TBG of 2.2 nM and greater than that of cleaved
wild-type TBG at 12.2 nM. This indicates that residues of this
whole connecting loop, including residues 104–106, influence
the hormone-binding site, most likely through interacting with
the neighboring connecting loop of s2/3B. Cleavage of the
reactive loop of the TBG-D3mutant increases itsKd to 50.7 nM.
This is only a 2-fold change and proportionately less than the
5.5-fold change observed on cleavage of wild-type TBG, which
corresponds to a 64% decrease in its sensitivity to the S-to-R
transition of TBG. Together, these findings further support the
notion that the connecting loop directly interacts with the hor-
mone-binding site (6) and plays a key role in stabilizing the
hormone-binding site. It also confirms that the connecting loop
is a key element in transmitting the S-to-R conformational
changes of TBG to the hormone-binding site.
The detailed interactions between the extended helix D con-
necting loop (hDs2A) and the binding site are seen in Fig. 2C.
There is little interaction between the D helix itself and the
adjacent loop of s4/5B that forms one flank of the binding site.
Instead, the potential linkage of the hDs2A loop to the thyrox-
ine-binding site is seen to be indirect, through its interaction
with the loop linking s2B and 3B, which is in turn linked to the
flanking s4/5B loop. Notably, in the TBG structures, the
extended connecting loop from helix D is in close contact with
Lys243, a conserved residue in the s2/3B loop in TBGs of various
species. The long side chain of Lys243 is bent, with its 
-carbon
pushed away from the connecting loop. Evidence of the critical
contribution of this linkage is seen with the loss of affinity and
increase in Kd from 2.2 nM to 3.1 and 7.5 nM on replacement of
Lys243 by the shorter side chains of Ala and Gly, respectively.
More marked changes in affinity are observed with their
cleaved forms (Table 2), with the Ala mutant being of lower
binding affinity but slightly more efficient in hormone release
(20% increase) and with the Gly mutation resulting in lower
binding affinity and inefficient hormone release following the
S-to-R transition of TBG (with a 27% decrease in hormone
release) compared with the wild-type. Together, these results
confirm the sensitivity of the linked transmission of changes in
the helixD connecting loop to the thyroxine-binding site. Inter-
estingly, these changes have been mirrored in a recently iden-
tified natural variant of CBG where the replacement of the
homologous residue, Gly237 in CBG, by a Val results in a drastic
decrease in affinity (28). The bulkier side chain of Val will pre-
dictably affect the packing between the hDs2A loop and s2/3B
loop with a consequent perturbation of the hormone-binding
site. Overall, the structural and functional findings show that
the loop on top of hD together with the s2/3B loop are integral
parts of the hormone-binding site.
Binding of T4 Analogues to TBG and Their Sensitivities to
S-to-R Transition—Further evidence showing how the changes
of hD affect the binding affinity of thyroxine comes from the
study of the binding by TBG of thyroxine analogues. The mod-
ified TBG, TBG-Atl, was selected for this study as its cleaved
form can be readily prepared and crystallized. It has a similarly
decreased hormone binding affinity following the S-to-R con-
formational changes to that of the wild-type TBG (as in Table
2). It appears that this variant is a more efficient thyroxine car-
rier than the wild-type with its native form having a higher
T4–6-CF binding affinity than that of wild-type, whereas its
cleaved form has lower binding affinity. It is likely that replace-
ment of the reactive loop affects the flip-flop movement of the
reactive loop and subsequent packing of -sheet A following
reactive loop insertion. This is consistent with previous find-
ings that changes in the reactive loop affect hormone binding
affinity (29, 30).
The binding affinities of four thyroxine analogues with TBG-
Atl conformers were measured using a competitive assay
involving the fluorophore T4–6-CF (Fig. 4) as described under
“Experimental Procedures,” and with the affinity of a fifth ana-
logue, 8-anilino-1-naphthalenesulfonate, being measured by
direct fluorescent titration. In general, the analogues bound
native TBG-Atl with Kd in the range of 89–304 nM and bound
the reactive loop cleaved TBG-Atl with Kd in the M range
(Table 3). However, the analogues differed in their sensitivities
to the S-to-R changes in TBG. This was especially so with furo-
semide, which binds the native form with a Kd of 123 nM and
binds the cleaved formwith aKd of 205 nM.This represents only
a 1.7-fold change in the Kd of furosemide following reactive
loop cleavage of TBG, whereas the binding of T4–6-CF or
mefenamic acid experiences a change of 13-fold. To under-
stand the structural basis of the difference in sensitivity of these
ligands toward the S-to-R transition of TBG, the crystal struc-
tures of furosemide and mefenamic acid complexed with reac-
tive loop cleaved TBG were solved at 1.7 and 2 Å resolution,
respectively (Table 1). The electron density of the two ligands
TABLE 2
The binding affinities of TBG towards T4–6-CF (22 °C). The affinity
changes, termed as the sensitivity to S-to-R transition, are then com-
pared with that of wild-type TBG.
Variants Native (Kd) Cleaved (Kd)
Affinity changes
(sensitivity to S-to-R)a
nM nM
TBG-WT 2.2 0.2 12.2 0.4  5.5 (100%)
TBG-D3 24.9 1.8 50.7 3.6  2 (36%)
TBG-K243A 3.0 0.1 20.4 1.2  6.8 (123%)
TBG-K243G 7.5 0.2 30.4 1.3  4.0 (73%)
a The responses to the S-to-R transitions of the mutants are compared with that of
TBG-WT.
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allowed their unequivocal placement in the binding pocket,
with binding seen to occur mainly through hydrophobic inter-
actions with residues lining the pocket (Fig. 4). Furosemide
forms a network of four hydrogen bonds with surrounding res-
idues, whereas mefenamic acid forms two, and the binding of
both ligands also involves similar -stackings of their aromatic
rings with the side chain of Arg381 and that of Tyr20, as seen in
the cTBG-thyroxine structure.However, there aremajor differ-
ences in the binding of the two ligands.Whereas the upper ring
of mefenamic acid, as with that of thyroxine, forms a direct
ionic interaction with the side chain of Arg378, furosemide with
a smaller upper ring has no direct interaction with Arg378. It is
also evident from overlays of the structures that the binding
pocket of TBG enclosing furosemide is slightly smaller than
those enclosing thyroxine and mefenamic acid. Thus, for a
ligand to be sensitive to the contraction of the hormone binding
pocket that constitutes the release mechanism, it must be opti-
mally sized and must also form interactions with the moving
part of the binding site, as shown here with the side chain of
Arg378.
Apart from forming a direct ionic interactionwith thyroxine,
the arginine at position 378 on the s4/5B loop is further stabi-
lized by interactions with residues Asp240, Tyr241, andAsp245 of
the adjacent s2/3B loop (Fig. 2C). Thus any movement of the
s2/3B loop (residues 240–245) will predictably affect the inter-
actions with Arg378, and consequently affect hormone binding.
The key contribution ofArg378 is confirmed herewith the study
of the R378Gmutant, TBG-Atl-R378G. The substitution of the
arginine with glycine results in a nearly 180-fold decrease in the
binding affinity of the native conformation with Kd increasing
from 1.6 to 291 nM.Moreover, this mutant is largely insensitive
to the S-to-R transition of TBG, with only a 4.8-fold increase in
theKd (1398 nM) of the cleaved form, as comparing to 15.2-fold
of the corresponding (nonmutated) TBG-Atl. This represents a
68% decrease in the response of TBG to the S-to-R transition
(Table 3). Therefore, Arg378 plays a key role for high affinity
binding of thyroxine in the hormone binding site and also its
subsequent release.
Direct Linkage between Reactive Loop and Hormone-binding
Site—Our preceding crystal structure of intact (uncleaved)
TBG-T4 showed the side chain of the reactive loop residue P14
(Thr342) poised for insertion into the -sheet A but sterically
blocked in doing so by the underlying Tyr241 in the s2/3B loop.
The spatial rearrangement required on reactive loop entry is
seen here in the cleaved TBG-T4 crystal structure (Fig. 5). The
full insertion of the side chain of Thr342 requires a rotation of its
side chain, resulting in the formation of a direct contact with
the protruding OH group of Tyr241. To demonstrate that this
rearrangement plays a role in hormone release, amutant (TBG-
Atl-Y241F) with Tyr241 replaced by the smaller Phe was pre-
pared and tested for its binding affinities before and after reac-
tive loop cleavage. The native conformer of this mutant has an
increasedKd of 2.6 nM, and the cleaved form has aKd of 29.7 nM
(Table 3), corresponding to a 11-fold change in binding affinity
following the S-to-R transition. Therefore, this direct interac-
tion between the reactive loop and the hormone site does
contribute to the hormone release (25% decrease in sensitiv-
ity to the S-to-R transition) but plays a lesser role than shifts in
hD in transmitting the S-to-R transitions to the hormone bind-
ing site. The significant (60%) decrease in affinity of intact
FIGURE 4. Binding of T4 analogues to TBG. The binding affinities of furosemide (A) or mefenamic acid (B) toward TBG conformers were measured by
competitive assaywith titration of the analogues into a TBG/T4–6-CFmixed solutionwith the fluorescence signalmonitored and fitted using the competitive
binding equations II and III. The fitted curves are shown in blue (cTBG) or green (native TBG). C and D, stereo-view of the binding site of cTBG-furosemide
complex (C) and cTBG-mefenamic acid (D). Electron density, contoured at 2.5 times the root mean square of the map for furosemide and 1 root mean square
formefenamic acid, is shown inbluemesh. Key residues are shown in stickswith carbonatomsare shown ingreen, nitrogenatomsare shown inblue, andoxygen
atoms are shown in red. Furosemide (C) forms four hydrogen bonds with surrounding residues, but it has no interaction with Arg378. The side chain of Arg378
is largely solvent exposed with little direct interaction with the binding site. Whereas in the cTBG-mefenamic acid structure (D), Arg378 exiting in alternative
conformations, forms ionic interactions with both the ligand and Asp240, similar to that of thyroxine (Fig. 2C). E and F, when these two structures are
superimposed with that of cTBG-thyroxine (gray), it is apparent that the furosemide-binding site (E, light blue) is slightly smaller and the side chain of Arg378
shifts away from the s2/3B loop and will thus be insensitive to its shifts. The side chain of Arg378 of the cTBG-mefenamic acid structure (F, green), however,
retains a similar position and hence responsiveness to the S-to-R change as that of cTBG-thyroxine.
TABLE 3
The binding affinities of thyroxine analogues towards native and cleaved TBG-ATL variant (22°C)
The affinities of ANSA were measured by directly titrating conformers of TBG-Atl variant into ANSA solution. The affinities of other compounds were obtained through the
competitive assay as described in “Experimental Procedures.”
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TBG-Atl-Y241F (Kd  2.6 nM) as compared with the corre-
sponding TBG-Atl (Kd  1.6 nM) and smaller changes in the
cleaved forms (from 24.4 to 29.7 nM) indicate that the con-
served Tyr241 plays a role in sterically impeding the further
insertion of the P14 residue and hence in fine-tuning the bind-
ing affinity of the native conformation.Mutation of this residue
with a Phe favors further insertion of the reactive loop into the
-sheet A and tips the equilibrium from stage II to III of Fig. 1D
resulting in the lower binding affinity of the native conformer.
Temperature Modulation of Binding Affinity—A corollary of
the flexibility and plasticity of the binding sites demonstrated
by the overall results is the likelihood of a modulated rather
than a direct on-off hormone releasemechanism. Our proposal
from the earlier structural studies (6) that the release of thyrox-
ine from TBG is potentially modulated by temperature, is con-
firmed here (Table 4) by the changes in binding affinities of the
T4 fluorophore at ambient temperature (22 °C) and normal
body temperature (37 °C). The prediction that increases in tem-
peraturewill affect hormone binding affinity were based on two
likely contributions, primarily the known effect from other ser-
pins (31) of increasing temperature on the opening of the
-sheet A and entry of the reactive loop and second, on the
predictable increased flexibility of the binding pocket at higher
temperature. Evidence that both factors contribute to the tem-
perature induced changes in TBG is seen in Table 4 with 2.5-
fold increase in Kd between 22 and 37 °C with wild-type TBG
versus the lesser 1.9-fold change with its cleaved form in which
the loop is fully inserted. The changes in CBG are more pro-
found, with a nearly 11-fold decrease in cortisol binding affinity
between 22° and 37 °C. The difference in sensitivity between
native TBG and CBG toward temperature is likely due to the
different configurations of reactive loop and -sheet A where
CBG has a closed -sheet A and fully exposed reactive loop,
whereas TBGhas a partially opened-sheet Awith the reactive
loop partially inserted.
DISCUSSION
During the past 20 years, crystallography has played a key
role in elucidating how the function of serpins as protease
inhibitors or hormone carriers is dependent on their unique
S-to-R conformational change. These studies show that serpins
are folded in a metastable conformation, which is normally in
an equilibration between different reactive loop-sheet configu-
rations. This dynamic equilibrium allows the allosteric modu-
lation of the functions of serpins, as seen in protease inhibition
by antithrombin (32) and more recently with hormone release
from TBG and CBG (6–8). However, each of the crystal struc-
tures in these studies represents just a single “frozen” confor-
mation and crystallographic structural studies alone are often
inadequate in illustrating the binding kinetics of a protein. For
example, native antithrombin binds heparin 30-fold more
tightly than its latent conformer; however, structures of native
and latent antithrombin complexed with heparin show that
heparin binds to the same site in latent as in native antithrom-
bin and induces similar conformational changes in the site (12,
33). Therefore, it is not surprising that in the crystal structures
of CBG cortisol binds to both native and cleaved conformers in
the sameway and, as also shown here, thyroxine binds to native
and cleaved TBG with identical interactions, even though the
cleaved conformers have lower hormone binding affinity. Sim-
ilarly, the dynamic nature of ligand-related changes in serpins
also iswell documented in antithrombin. The activation of anti-
thrombin induced by binding to the heparin pentasaccharide
was shown in an initial structure (12) to be due to the full expul-
sion of its reactive center loop. But, subsequently, a second
structure of the liganded antithrombin showed the loop to be
partially inserted into the -sheet A (13). Thus, these two fro-
zen depictions illustrate the dynamic movement of the loop
that take place in and out of the -sheet A, giving the equili-
brated changes in activity and affinity thatwe believe is also true
of TBG and CBG, as illustrated schematically in Fig. 1D.
To dissect the detailedmechanism involved in hormone car-
riage and release, we have complemented our crystallographic
structural studies by developing a sensitive fluorescent method
for measuring the binding affinity of TBG. This allows us to
demonstrate unequivocally that although cleavage of the reac-
tive loop in TBG results in a markedly lowered affinity, the
cleaved form still binds thyroxine with an affinity that greatly
exceeds the binding affinity of intact uncleaved TBG for drugs
FIGURE 5. The direct interactions between the reactive loop and the hor-
mone-binding site in stereo. A, in the native TBG-T4 complex, the reactive
loop is partially inserted in the central -sheet A (blue) with P14 residue
(Thr342) impeded from further insertion by the underlying Tyr241 from the
S2/3B connecting loop (purple). B, in the cleaved TBG-T4 structure, the reac-
tive loop is fully inserted into the central -sheet A with the side chain of
Thr342 forming a direct contact with the OH group of Tyr. The -sheet B is
colored in yellow.
TABLE 4
The temperature effect on the binding affinity of TBG and CBG con-
formers
Temperature
TBG (Kd) CBG (Kd)a
Native Cleaved Native Cleaved
nM nM nM nM
22 °C 2.1 0.2 12.1 0.4 26.9 2.4 N.D.
37 °C 5.6 0.1 23.4 0.6 292.2 19.0 1366.0 123.5
aWe note that the Kd values for recombinant CBG determined here differ from
those of our colleagues (36); the differences are in absolute values rather than in
principle and do not affect the conclusions in the earlier paper. N.D., not
determined.
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such as furosemide that are considered to compete in vivo for
binding with thyroxine (34). We also show here that cleaved
CBG can still effectively complex with cortisol (Table 3). This is
contrary to the prevailing view in the field that hormone release
following reactive loop cleavage results from the irreversible
destruction of the hormone-binding site (35).
Taken together with the parallel studies of antithrombin, the
results here provide an explanation of the changes in binding
affinity that accompany each stage of reactive loop insertion in
the hormone-binding globulins, as in Fig. 1D, I–IV. In I, the
shorter reactive loop of CBG is fully exposed in what will be a
high affinity state. In the lower affinity state II, the longer loop
in TBG is already partly inserted into the -sheet A but will
predictably readily fluctuate between the two conformations. It
is at this stage, from I to II, that the expansion of the -sheet A
and the unwinding of the top of the D helix takes place in anti-
thrombin. We believe it is this equilibrated transition between
steps I and II, with the changes in the proportional population
of each, that accounts for the changes in affinity in the hor-
mone-binding globulins and allows modulated hormone bind-
ing. Hence, any changes that favor full loop expulsionwill result
in increased binding affinity, as shown previously with an engi-
neered shortening of the reactive loop of TBGbyGrassberger et
al. (29). Conversely, changes that favor a shift beyond the partial
insertion in II will result in decreased affinity as shown previ-
ously with extended reactive center loop and here with the
replacement of the conserved Tyr241 that otherwise sterically
impedes further loop extension. The complete and irreversible
expansion of the -sheet A, with a major loss of affinity, occurs
with the full insertion of the cleaved reactive loop, as in IV.
As confirmed here, the connecting loop on top of the hD is
the keymediator in transmitting themovements of the reactive
loop to the hormone-binding site with shortening of it by three
residuesmaking themutant insensitive to the S-to-R transition.
As summarized in Fig. 6, the connecting loop is seen in the
structures of TBG to be linked to residues in the s2/3B loop,
which in turn interacts with the s4/5B loop, and especially so
with Arg378, which directly flanks the binding site. It is the close
packing of these loops that allows the transmission of the
expansion of -sheet A to give a perturbation of the binding
pocket that in TBG will favor the release of the tightly fitting
thyroxine but will have a lesser effect on smaller ligands, as
shown here with furosemide.
Althoughwehave focusedhere onhow themovements of the
helix D are associated with the changes in the hormone binding
site, changes in other part of TBG following reactive loop inser-
tion likely also contribute to the changes in the binding affinity,
such as the shifts of hA following themovements of the reactive
loop as shown in Fig. 2B and supplemental Fig. S1. Overall, we
conclude it is the inherent plasticity of both TBG and CBG,
the key feature of the serpin-fold, in contrast to other hormone
carriers such as albumin, that provides the potential for subtle
modulation of hormone binding and release. We demonstrate
this here with TBG in response to changes in ambient temper-
ature, as we have also shown with our colleagues in CBG, with
physiological changes in body temperature (36).
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